Psyence Group (TSE:PSYG) has released an update.
Psyence Group’s associate, Psyence Biomedical, has initiated a clinical trial in Australia to study the effects of nature-derived psilocybin on Adjustment Disorder in palliative care. The Phase IIb study will be supported by partnerships with Fluence and iNGENū CRO Pty Ltd, and marks progress in exploring psilocybin’s potential for treating mental health conditions.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.
